Articles from HAYA Therapeutics

HAYA Therapeutics SA, a clinical-stage biotechnology company pioneering precision RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states in common, chronic and age-related diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase 1a/b trial, with the first cohort dosed this past May.

HAYA Therapeutics SA, a clinical-stage biotechnology company pioneering precision RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states in common, chronic, and age-related diseases, announced that the first cohort has been fully enrolled and dosed in the company’s Phase 1 clinical trial evaluating HTX-001, its first-in-class long non-coding RNA (lncRNA)-targeting therapy for nonobstructive hypertrophic cardiomyopathy (nHCM).

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has relocated its U.S. site to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc.

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, and chronic diseases, announced that Dr. Richard Law has joined as Chief Business Officer. With more than two decades of experience in drug discovery and business development, Dr. Law brings tremendous expertise in creating biopharma partnerships, shepherding company growth, and securing life sciences funding.

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced that Jordan Shin, M.D., Ph.D. has joined as Chief Medical Officer (CMO). As a veteran with over a decade in the cardiovascular and lung spaces and translational experience with genetic medicines, Dr. Shin will be instrumental in bringing HAYA’s therapeutics, including lead candidate HTX-001 in development for non-obstructive hypertrophic cardiomyopathy, to the clinic and to patients.

HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that HAYA’s Co-Founders Samir Ounzain and Daniel Blessing have received the inaugural Andreas & Thomas Struengmann Award.

HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as Chairperson of the Board of Directors. Dr. Thomas, CEO and Founder of Metagenomi, brings extensive experience in biotech research and development.

HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced that Innosuisse, the Swiss Innovation Agency, is supporting two research collaboration projects between HAYA and the University of Bern, University Hospital of Bern and Lausanne University Hospital. Innosuisse is funding 50 percent of the total project costs of approximately CHF 3.1 million (US$3.3 million).

HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced that the company has established a new laboratory space at JLABS @ San Diego, part of Johnson & Johnson Innovation’s global network of life science incubators.

HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its Scientific Advisory Board (SAB). The group of world-renowned leaders and pioneers are recognized for their work in lncRNA biochemistry, cardiovascular disease, antisense technology and fibrotic diseases, and will work closely with HAYA to support the company’s mission to bring novel anti-fibrotic therapies to the clinic.